Beam Therapeutics Inc. (NASDAQ:BEAM) Financings
Financings
| Raise | Date |
|---|---|
| Public offering of common stock and pre-funded warrants Announced: about US$500M · US$28.48 a share · J.P. Morgan +4 Dealers: J.P. Morgan (co-lead), Jefferies (co-lead), Cantor (co-lead), Citigroup (co-lead), Wells Fargo Securities (co-lead) Use of proceeds: Advancing its base editing platform and programs, BEAM-101 BLA and pre-commercial work, BEAM-302 and ESCAPE trials, and general corporate purposes | Mar 10, 2025 |